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Background: Protein-based therapeutics represent the fastest growing class of compounds in the pharmaceutical
industry. This has created an increasing demand for powerful expression systems. Yeast systems are widely used,
convenient and cost-effective. Yarrowia lipolytica is a suitable host that is generally regarded as safe (GRAS). Yeasts,
however, modify their glycoproteins with heterogeneous glycans containing mainly mannoses, which complicates
downstream processing and often interferes with protein function in man. Our aim was to glyco-engineer
Y. lipolytica to abolish the heterogeneous, yeast-specific glycosylation and to obtain homogeneous human high-
mannose type glycosylation.
Results: We engineered Y. lipolytica to produce homogeneous human-type terminal-mannose glycosylated
proteins, i.e. glycosylated with Man8GlcNAc2 or Man5GlcNAc2. First, we inactivated the yeast-specific Golgi α-1,6-
mannosyltransferases YlOch1p and YlMnn9p; the former inactivation yielded a strain producing homogeneous
Man8GlcNAc2 glycoproteins. We tested this strain by expressing glucocerebrosidase and found that the
hypermannosylation-related heterogeneity was eliminated. Furthermore, detailed analysis of N-glycans showed that
YlOch1p and YlMnn9p, despite some initial uncertainty about their function, are most likely the α-1,6-
mannosyltransferases responsible for the addition of the first and second mannose residue, respectively, to the
glycan backbone. Second, introduction of an ER-retained α-1,2-mannosidase yielded a strain producing proteins
homogeneously glycosylated with Man5GlcNAc2. The use of the endogenous LIP2pre signal sequence and codon
optimization greatly improved the efficiency of this enzyme.
Conclusions: We generated a Y. lipolytica expression platform for the production of heterologous glycoproteins
that are homogenously glycosylated with either Man8GlcNAc2 or Man5GlcNAc2 N-glycans. This platform expands
the utility of Y. lipolytica as a heterologous expression host and makes it possible to produce glycoproteins with
homogeneously glycosylated N-glycans of the human high-mannose-type, which greatly broadens the application
scope of these glycoproteins.* Correspondence: Nico.Callewaert@dmbr.vib-UGent.be
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The production of biopharmaceuticals, which are in-
creasingly dominating the pharmaceutical industry,
requires powerful heterologous expression systems.
Lately, yeast expression hosts have attracted much
interest for several reasons. They are easy to handle,
they grow rapidly on simple, chemically defined media,
they are cost effective, there is no risk of contamination
with infectious agents originating from animal products,
and they can efficiently secrete recombinant proteins,
which simplifies downstream processing. But one of the
most important features of yeast expression systems is
their ability to perform eukaryotic post-translational
protein modifications, such as N- and O-glycosylation,
disulfide bond formation, and oligomerization, which
are often crucial for the functionality of therapeutic
glycoproteins.
However, mammalian cells and yeast cells share only
the initial stages of the N-glycosylation pathway, and so
their glycosylation patterns are very different. Yeasts
modify proteins with heterogeneous high-mannose
glycan structures by the action of yeast-specific Golgi
mannosyltransferases. In some cases, this leads to hyper-
mannosylation (Figure 1A, top). Hypermannosylation in
yeasts increases heterogeneity, can hamper downstream
processing, and can even lead to an immunogenic re-
sponse in humans. On the contrary, in mammalian cells,
high-mannose N-glycans exiting the endoplasmic
reticulum (ER) are trimmed to Man5GlcNAc2 in the
Golgi and are usually further modified into complex-
type glycans (Figure 1A, bottom). To adapt yeast for the
production of biopharmaceuticals, the endogenous yeast
glycosylation pathway can be engineered to produce gly-
coproteins with homogeneous human high-mannose
type glycans (Figure 1B).
Terminal mannosylation of glycoproteins is useful for
several applications. For example, successful antibody-
directed enzyme pro-drug therapy (ADEPT) requires
rapid tissue clearance of the drug. For instance, the man-
nosylated antibody–enzyme fusion protein MFECP1,
which selectively targets tumor cells, is cleared by the
endocytic and phagocytic mannose receptor (MR) [1].
Another example is the use of mannosylated proteins in
enzyme replacement therapy (ERT), such as the use of
glucocerebrosidase for patients with type 1 Gaucher
disease. In this case, the terminal mannose residues on
the glycans are essential for targeting glucocerebrosidase
to the mannose receptors of Gaucher macrophages,
where most abnormal accumulation of glucocerebroside
occurs [2-5].
Yarrowia lipolytica is a yeast expression system
used for the production of heterologous proteins for
therapeutic purposes [6]. It has GRAS-status (generally
recognized as safe) and grows to very high cell densitieson long-chain fatty acids. Moreover, the promoter
for peroxisomal fatty-acyl-CoA oxidase 2 (Pox-2) can
be used for inducible protein expression. In this study,
we engineered the Y. lipolytica expression system for
the production of homogeneous, human-type high-
mannose glycosylated proteins, i.e. glycosylated with
Man8GlcNAc2 or Man5GlcNAc2. We inactivated the
yeast-specific Golgi α-1,6-mannosyltransferase-genes,
OCH1 and MNN9 [7,8], which yielded a strain with
very homogeneous Man8GlcNAc2 glycoproteins. To
demonstrate the efficacy of this engineered strain, we
overexpressed glucocerebrosidase. Further engineering
involved the introduction of an ER-retained α-1,2-man-
nosidase. The resultant strain produced homogeneous
Man5GlcNAc2 sugar structures on its glycoproteins.
Results
Man8GlcNAc2 N-glycan engineering by inactivating the
α-1,6-mannosyltransferases OCH1 and MNN9
Creating a Y. lipolytica strain that homogeneously attaches
Man8GlcNAc2 N-glycans to recombinant glycoproteins
requires engineering of the yeast N-glycosylation pathway
at the Golgi level. Glycoproteins containing Man8GlcNAc2
glycans are typically elongated in the Golgi of yeast,
which often results in hypermannosylation. To avoid this,
we inactivated the OCH1 gene, which encodes the Golgi
α-1,6-mannosyltransferase (α-1,6ManT), which initiates
hypermannosylation. Though this strategy has been suc-
cessfully implemented in other yeasts [9], there have
been some doubts about which of the α-1,6-mannosyl-
transferase-homologous genes in Y. lipolytica codes for
this initiating transferase. It was first suggested that
YlOch1p (the protein most homologous to the Sacchar-
omyces cerevisiae Och1p) might play only a minor role
in outer-chain elongation of N-glycosylation [10], but
this was later contradicted [11]. Furthermore, in the
original study, more severe glycosylation defects were
observed when this MNN9 gene was inactivated than
when the OCH1 gene was inactivated, which led to the
proposal that Y. lipolytica Mnn9p plays a major role in
the Golgi N-glycosylation pathway [10]. Accordingly,
we investigated the effect of knocking out OCH1 and
MNN9 by comparing strains with single and double
knock-outs of OCH1 and MNN9.
After inactivation of the OCH1 gene, N-glycan analysis
was performed on mannoproteins prepared from the
wild-type MTLY60 and the Δoch1 mutant strain. On the
glycoproteins of the Δoch1 mutant, the sugars were al-
most exclusively Man8GlcNAc2 with a minor fraction of
Man9GlcNAc2 glycans (Figure 2E). But in the wild-type
strain the oligosaccharides were more heterogeneous in
size, mostly Man8GlcNAc2, Man9GlcNAc2 and larger
oligosaccharides (Figure 2C). In vitro α-1,2-mannosidase
digestion trimmed the labeled N-glycans derived from
Figure 1 N-glycosylation in wild type strains and the approach used to engineer the yeast pathway. (A) Standard N-glycosylation in yeast
and mammalian cells. The early N-glycan steps in the ER are strongly conserved between higher and lower eukaryotes until the stage at which
folded proteins bearing the eukaryotic common high mannose Man8GlcNAc2 glycan structure (isomer B) leave the ER and enter the Golgi
apparatus. At this point, the glycans undergo further species and cell-type specific processing. The pathways in the Golgi complex diverge
notably. In higher eukaryotes, the Man8GlcNAc2 structure is further trimmed to Man5GlcNAc2 by mannosidase I and can then be further modified
to complex glycans (bottom). In yeast, the Man8GlcNAc2 glycan structure is further elongated with mannoses by mannosyl- and
phosphomannosyltransferases, and in some cases this results in hypermannosylation (top). (B) Glyco-engineering in yeast. A knock-out of the
OCH1 gene prevents the elongation of Man8GlcNAc2 glycans (isomer B), and upon expression of the HDEL-tagged α-1,2-mannosidase,
Man5GlcNAc2 glycans are formed. Conforming to the representation proposed by the Consortium for Functional Glycomics Nomenclature
Committee, the green and yellow spheres represent mannose (Man) and galactose (Gal), respectively, blue squares represent N-acetylglucosamine
(GlcNAc) residues and the red diamonds represent sialic acid (Sia).
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indicating that no α-1,6-mannose residue was added in
the Golgi apparatus of this strain (Figure 1A, top). α-1,2-
mannosidase digestion of the mannoprotein N-glycans
from the wild-type strain also yielded Man5GlcNAc2.
Also, a fraction of the glycans were converted to struc-
tures larger than Man5GlcNAc2 (Figure 2D), likely due
to elongation with α-1,6-mannose residues.
Before inactivation of Mnn9p (another α-1,6-manno-
syltransferase homolog), the Δoch1 mutant strain wasfirst cured of its lox-flanked URA3 marker gene. To
that end, we used the Cre-lox recombination system,
which is based on transformation of a transient episo-
mal plasmid containing a cassette for expression of Cre
recombinase. The MNN9 gene was then knocked out
in the Y. lipolytica MTLY60 wild type strain and the
URA3-cured Δoch1 strain. Next, we analyzed the
mannoprotein N-glycans derived from these strains.
The Δmnn9 mutant accumulated mostly Man9GlcNAc2
N-glycans and some Man8GlcNAc2 (Figure 2G). The
Figure 2 (See legend on next page.)
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Figure 2 DSA-FACE analysis of mannoprotein N-glycans derived from different Yarrowia lipolytica strains. (A) Oligomaltose reference.
(B-J) Different N-glycans. (B) Bovine RNaseB reference. (C) the MTLY60 wild type strain. (D) The same as panel C but treated with α-1,2-mannosidase.
(E) The Δoch1 mutant strain. (F) The same as panel E but treated with α-1,2-mannosidase. (G) The Δmnn9 mutant strain. (H) The same as
panel G but treated with α-1,2-mannosidase. (I) The Δoch1 Δmnn9 mutant strain. (J) The same as panel I but treated with α-1,2-mannosidase.
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Man5GlcNAc2 by α-1,2-mannosidase digestion (Figure 2H).
Moreover, glycosylation in the double mutant (Δoch1/
Δmnn9) resembled that in the Δoch1 strain (Figure 2I).
The N-glycans of this double mutant could be con-
verted to Man5GlcNAc2 by α-1,2-mannosidase digestion
(Figure 2J). These data are compatible with the notion that
the Y. lipolytica Mnn9p, like its S. cerevisiae counterpart
[12], is the α-1,6-ManT that attaches the second α-1,6-
mannose to the glycan backbone after attachment of
Och1p α-1,6-mannose.
The impact of glycan engineering on the growth of
these engineered strains was assessed by growth curve
analysis. The inactivation of the Golgi α-1,6-mannosyl-
transferase Yloch1 has no detrimental effect on the
growth rate in either YPD or YTO (Figure 3 A and B).
We conclude that YlOCH1, as in other yeasts [7,13-16],
is the initiating α-1,6-mannosyltransferase that is respon-
sible for the yeast high mannose structures and thereby
confirm the results obtained by Song et al. [11]. TheΔoch1
Y. lipolytica strain generates an N-glycan profile that is
estimated >85% Man8GlcNAc2, which is the high-man-
nose glycan present on proteins exported from the ER in
most eukaryotes, including humans.
Human glucocerebrosidase expression
The human glucocerebrosidase sequence [GLCM, Swiss
Prot entry No. P04062] was synthesized as cDNA
codon-optimized for expression in Y. lipolytica. The
coding sequence for the mature protein (amino acids
40 to 536) was fused to the coding sequence of the
LIP2pre signal sequence. This fusion construct was
cloned under control of the oleic-acid-inducible POX2
promoter and transformed to the Y. lipolytica wild-type
strain MTLY60 and the Δoch1 mutant strain. Both
transformants were grown, and proteins were precipi-
tated from the supernatant, separated by SDS-PAGE,
and immunoblotted using a rat monoclonal anti- gluco-
cerebrosidase antibody [17]. In representative immuno-
blots, the Δoch1 strain shows no smearing (Figure 4,
lane 2), whereas WT cells show heterogeneity of the
glycoprotein (Figure 4, lane 1). We conclude that inacti-
vation of Och1p at least abolishes hypermannosylation
on the test protein glucocerebrosidase.
Glucocerebrosidase was purified from a Y. lipolytica
Δoch1 mutant strain's supernatant by a combination of
cation and anion exchange chromatography and gel filtra-
tion chromatography. The purified glucocerebrosidasefrom the Y. lipolytica Δoch1 mutant strain had a spe-
cific activity on 4-Nitrophenyl-β-D-glucopyranoside of
2.5 +/− 0.8 units/mg, whereas a batch of currently used
therapeutic glucocerebrosidase (Cerezyme, Genzyme
Corp.) had a specific activity of 5.6 +/− 0.5 units/mg.
The reason for the somewhat lower specific activity of
our recombinant enzyme is most probably that no
efforts have yet been done to fully optimize the fermen-
tation, purification and formulation of this rather labile
enzyme, contrary to what is the case for the clinically
used Cerezyme preparations. Nevertheless, the results
clearly show that the glucocerebrosidase produced in
glyco-engineered Y. lipolytica is enzymatically active.
Man5GlcNAc2 N-glycan engineering
Expression of T. reesei α-1,2-mannosidase
To further humanize the N-glycans of Y. lipolytica to
Man5GlcNAc2, an ER-retained Golgi-type α-1,2-manno-
sidase was expressed in the URA3-cured Δoch1 strain.
The use of an HDEL-tagged T. reesei α-1,2-mannosidase
[Genbank® Accession No. AF212153] had proven its ef-
fectiveness in hydrolyzing α-1,2-linked mannose residues
in vivo in Pichia pastoris [18] as well as in Aspergillus
niger [9]. Therefore, we chose this approach to trim
down the α-1,2-linked mannoses in the Man8GlcNAc2
N-glycans of the Δoch1 strain to produce Man5GlcNAc2
N-glycans. The HDEL tag is used to target the enzyme
to the ER-Golgi boundary, where its Man8GlcNAc2 sub-
strate is formed.
First, we tried overexpressing the mannosidase fused
to the S. cerevisiae α-mating factor prepro sequence
under control of the constitutive hp4d promoter
(pYLHmAXMFManHDEL) in the URA3-cured Δoch1
strain, but with very poor results. The mannoprotein
N-glycan profiles show that only a minor fraction of
Man8GlcNAc2 was converted to Man5GlcNAc2
(Figure 5D).
Expression of T. reesei α-1,2-mannosidase using LIP2pre
as secretion signal
The incomplete trimming of Man8GlcNAc2 to Man5-
GlcNAc2 might have been due to a non-optimal signal
sequence. Therefore, we replaced the Saccharomyces
cerevisiae α-MF prepro sequence with the secretion sig-
nal of the strongly expressed Y. lipolytica LIP2 gene
(LIP2pre) and fused it to the coding sequence of the
mannosidase, and subsequently transformed the cassette
from the pYLHmAXL2preManHDEL construct to the
Figure 3 Growth curve determination of different Yarrowia
lipolytica strains. (A) Growth behavior in YPD medium of wild type
strain MTLY60 (♦), Δoch1 strain (■) and Δoch1 strain overexpressing
a TEF promoter driven, HDEL-tagged α-1,2-mannosidase (▲). (B)
Growth behavior in oleic acid induction medium YTO of wild type
strain MTLY60 (♦), Δoch1 strain (■) and Δoch1 strain overexpressing
a TEF promoter driven, HDEL-tagged α-1,2-mannosidase (▲).
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GlcNAc2 to Man5GlcNAc2 occurred, but the reaction
was again incomplete (Figure 5E) (Man8GlcNAc2 was
present as well as the intermediate products Man7-
GlcNAc2 and Man6GlcNAc2). It should also be noted that
much clonal variation was observed (data not shown).
Expression of T. reesei α-1,2-mannosidase after codon
optimization for Y. lipolytica
To further improve the α-1,2-mannosidase activity, we
optimized codon usage and GC content of the mannosi-
dase sequence for expression in Y. lipolytica. Four differ-
ent promoters were used to express the codon-
optimized T. reesei α-1,2-mannosidase in fusion with
the LIP2pre signal sequence and the HDEL retrieval
signal. These were (i) hp4d, a Y. lipolytica hybrid
promoter created by Madzak et al. [19], (ii) GAP,
the Y. lipolytica strong constitutive glyceraldehyde-3-
phosphate dehydrogenase promoter, (iii) TEF1, the
Y. lipolytica strong constitutive promoter for trans-
lation elongation factor 1, and (iv) POX2, Y. lipolytica
peroxisomal fatty-acyl-CoA oxidase2 promoter. All four
plasmids (pYLHUXL2preManHDEL, pYLGUXL2pre-
ManHDEL, pYLPUXL2preManHDEL and pYLTUXL2-
preManHDEL) were transformed to the Y. lipolytica
URA3-cured Δoch1 mutant strain. The resulting
strains were grown in YPD or YTO (for POX-driven
expression). All constructs resulted in full conversion of
cell wall mannoprotein N-glycans to Man5GlcNAc2
(Figure 5, panels F-H). To evaluate whether this would still
be true in protein production conditions, all strains were
analyzed after growth in the presence of oleic acid for 72 h.
Again full conversion was observed (Figures 5, Panels I-L).
As depicted in Figure 3, the introduction of the ER retained
α-1,2-mannosidase does not severely impede growth of the
engineered Y. lipolytica strain in either YPD or oleic acid
induction medium (YTO). At the stationary phase, how-
ever, the optical density reached is lower, although not sta-
tistically significant, for the engineered than for wild type
strain; a phenomenon that is seen in other glyco-engineered
yeast types [9,15].
We conclude that using a signal sequence native to
Y. lipolytica and optimizing codon usage and GC con-
tent can greatly improve the function of an enzyme
expressed heterologously in Y. lipolytica.
Discussion
We engineered the Y. lipolytica expression system to pro-
duce glycosylated proteins with homogeneous human-type
N-glycans with terminal mannose, i.e. Man8GlcNAc2
or Man5GlcNAc2. To this end, we inactivated the
Y. lipolytica genes that are homologous to the α-1,6-manno-
syltransferase-coding sequences OCH1 and MNN9 [7,8].
Analysis of the N-glycan profile of cell wall mannoproteins
Figure 4 Western blot evaluation of hypermannosylation of glucocerebrosidase before and after inactivation of YlOCH1. Expression of
glucocerebrosidase by the wild-type strain (WT, MTLY60) (lane1) and by the Δoch1 mutant strain (lane2). The WT strain shows a smear,
indicating hyperglycosylation, while the Δoch1 mutant strain shows a distinct band above 55 kDa, which is the MW of glucocerebrosidase
without sugars.
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lated the Man8GlcNAc2 precursor glycan. These results
are in agreement with a previous report [11]. Thus,
though the function of Och1p in Y. lipolytica had been
questioned [10], we conclude that the Y. lipolytica Och1p,
like the S. cerevisiae α-1,6-mannosyltransferase Och1p
[7,13,20,21], is critical for the extension of N-linked oligo-
saccharide chains, and that it is at least responsible for the
addition of the first α-1,6-linked mannose to the core
Man8GlcNAc2 oligosaccharide.
Moreover, we show that the hypermannosylation-
related heterogeneity of glucocerebrosidase is abolished
in the Δoch1 knock-out strain. Our experiments indicate
that the Y. lipolytica Mnn9p, like the S. cerevisiae α-1,6-
mannosyltransferase Mnn9p [12], is responsible for the
attachment of the second α-1,6-mannose to the glycan
backbone following Och1p activity.After generating the Δoch1 mutant strain producing
Man8GlcNAc2, we introduced an ER-retained variant of a
T. reesei α-1,2-mannosidase. The resultant strain showed
homogeneous Man5GlcNAc2 sugar structures on its glyco-
proteins. Several optimizations were necessary to get to this
point. Comparing the best clone of both transformations,
the secretion signal of the endogenous strongly expressed
and secreted protein lipase2 was more effective than the
often-used S. cerevisiae α-MFprepro signal. Moreover, we
had to adapt the coding sequence, GC content (to about
50.5% GC) and codon usage to that of Y. lipolytica. Codon
optimization has been used effectively to increase the ex-
pression of heterologous proteins in many hosts. A recent
study demonstrated that codon optimization in Y. lipolytica
increased heterologous protein production eleven-fold [22].
From our study we conclude that such optimization is also
crucial for expressing the T. reesei α-1,2-mannosidase.
Figure 5 DSA-FACE analysis of N-glycans derived from
different Yarrowia lipolytica strains. (A) Oligomaltose reference.
(B-L) Different N-glycans. (B) Bovine RNaseB reference. (C) The
MTLY60 wild type strain. (D-E) HDEL-tagged α-1,2-mannosidases
expressed in a Δoch1 background: (D) the mannosidase fused to the
S. cerevisiae α-mating factor prepro sequence and (E) the mannosidase
fused to the Y. lipolytica LIP2pre. (F-L) The codon-optimized mannosidase
fused to the Y. lipolytica LIP2pre: (F) under control of the hp4d promoter
and grown in YPD, (G) under control of the GAP promoter and grown in
YPD, (H) under control of the TEF promoter and grown in YPD, (I) under
control of the hp4d promoter and grown in YTO, (J) under control of
the GAP promoter and grown in YTO, (K) under control of the TEF
promoter and grown in YTO, (L) under control of the POX promoter and
grown in YTO.
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Y. lipolytica expression platform for the production
of heterologous glycoproteins that are homogenously
glycosylated with either Man8GlcNAc2 or Man5GlcNAc2
N-glycans, which greatly broadens the application scope
of proteins produced in this organism.Material and methods
Strains, culture conditions, reagents and growth curve
determination
Escherichia coli strains MC1061, TOP10 and DH5α were
used for the amplification of recombinant plasmid DNA.
Y. lipolytica MTLY60 [23] and W29 [24] were used as
parent strains. All yeast strains were cultured at 28°C.
The media were the following: YPD (10 g/L yeast ex-
tract, 20 g/L bacto-peptone, and 20 g/L dextrose); YTO
(10 g/L yeast extract, 20 g/L tryptone, 2% vol oleic acid,
0.05% vol Tween 40, 10 g/L dextrose, and 50 mM K+/Na
+ phosphate buffer pH 6.8; emulsified oleic acid was
added after autoclaving); MM (1.7 g/L YNB without AA
and ammonium sulphate, 10 g/L glucose, 5 g/L NH4Cl,
50 mM K+/Na+ phosphate buffer pH 6.8, and 7.7 g/L
Complex Serum-free Medium (CSM) (MP Biomedicals,
Santa Ana, CA, USA), and for selection of Ura+ and Leu
+ transformants, 7.7 g/L CSM –ura or CSM –leu was
added instead of CSM).
To determine the growth curves of the different
strains, yeast cultures started from singles colonies
grown on solid YPD medium were grown overnight in
liquid YPD medium. These precultures were used to in-
oculate 125 mL shake flasks containing 30 mL medium
(YPD or YTO), to obtain an initial optical density at
600 nm (OD600) of 0.2. These cultures were grown at
28°C with rotation at 250 rpm and the OD600 was deter-
mined every few hours. All strains were examined in
parallel in the same experiment.Standard genetic techniques
Competent Y. lipolytica cells were prepared as described
by Barth and Gaillardin [25]. Briefly, plasmid DNA to-
gether with salmon sperm carrier DNA was added to
cells pretreated with lithium acetate. PEG 4000 was then
added, and after a heat shock at 39°C, the cells were pla-
ted on selective plates.
Genomic DNA was isolated using the MasterPureTM
Yeast DNA Purification Kit according to the manufac-
turer’s instructions (Epicenter Biotechnologies, Madison,
Winsconsin). PCR amplification was performed in a vol-
ume of 50 μl containing 20 mM Tris–HCl pH 8.4,
50 mM KCl, different concentrations of MgCl2 and
DMSO, 0.4 mM of dNTPs, 50 ng of template DNA, 50
pmol of primers and 2.5 units of either Taq or Pfu DNA
polymerase. Cycling conditions were as follows: denatur-
ation at 95°C for 5 min followed by a hot start at 80°C
and 30 cycles of 95°C for 30 s, suitable annealing
temperature for 30 s and extension at 72°C for 1.5 min,
followed by 10 min of final extension at 72°C.
DNA fragments were purified from PCR reactions and
gels by using NucleoSpin extract II (Macherey-Nagel,
Düren, Germany).
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Knock-out of the OCH1 gene
The OCH1 gene [GenBank® Accession No: AJ563920],
complete with its promoter and its terminator, was amp-
lified from genomic DNA of Y. lipolytica W29 by PCR
with primers OCH1Pfw and OCH1Trv (Table 1), using
Pfu DNA polymerase (Fermentas, Burlington, Ontario,
Canada). The amplified fragment was cloned in pCR-
BluntII-TOPO (Invitrogen, Carlsbad, CA, USA). The
promoter (P) and terminator (T) regions were amplified
from this plasmid using, respectively, primers OCH1Pfw
and OCH1Prv and primers OCH1Tfw and OCH1Trv
(Table 1). Because of overlapping primer sequences con-
taining an I-SceI restriction site, the two fragments could
be linked by PCR with the OCH1Pfw and the OCH1Trv
primers. This co-amplicon was subcloned in a pCR-Blun-
tII-TOPO vector and Sanger-sequenced. The URA3
selection marker flanked by lox sites and derived from
the pKS-LPR-URA3 plasmid [26] was inserted in the
introduced I-SceI site between P and T to produce
pYlOCH1-PUT. The desired fragment was PCR amplified
with the OCH1Pfw and OCH1Trv primers and trans-
formed to the Y. lipolytica MTLY60 wild type strain. Two
out of twenty URA prototrophic clones found by PCR on
gDNA to be Δoch1 were confirmed by Southern blot.Knock-out of the MNN9 gene
The promoter fragment (P) of the MNN9 gene [GenBank®
Accession No: AF441127] was amplified from genomic
DNA of the Y. lipolytica MTLY60 strain by PCR using Taq
polymerase and the MNN9Pfw and MNN9Prv primers
(Table 1). The terminator fragment (T) of the MNN9 gene
was amplified from the same DNA using primers
MNN9Tfw and MNN9Trv (Table 1) and Taq polymerase.
Again, overlap PCR with the P-forward primer and theTable 1 PCR primers and oligonucleotides












ManHDELrv GGCCCTAGGTTACAACTCGTCGTGAGCAAGT-reverse primer was used to link the two fragments. This
co-amplicon was subcloned NotI–PacI in pCR-II-TOPO-TA
and Sanger-sequenced. The URA3 selection marker
flanked by lox sites and derived from pKS-LPR-URA3
was inserted in the introduced I-SceI site between P
and T to produce pYlMNN9-PUT. The desired frag-
ment was excised by NotI–PacI double digestion and
transformed to the Y. lipolytica MTLY60 wild type
strain and the URA3-cured Δoch1 strain. Several URA
prototrophic clones were screened by PCR on gDNA to
confirm correct integration of the construct.Expression of the trichoderma reesei α-1,2-mannosidase
HDEL
Plasmid pYLHmAXMFManHDEL was constructed to ex-
press the Trichoderma reesei α-1,2-mannosidase [Genbank®
Accession No. AF212153] fused to the Saccharomyces cere-
visiae prepro mating factor, tagged with a C-terminal HDEL
sequence [27] and under control of the constitutive hp4d
promoter [19]. The expression cassette was transformed
into the Y. lipolytica Δoch1 strain after digestion of the
plasmid with NotI, followed by isolation of the desired
fragment using agarose-gel electrophoresis.
In another construct (pYLHUdL2preManHDEL), the S.
cerevisiae secretion signal was replaced with the secre-
tion signal of the Y. lipolytica LIP2 gene (LIP2pre). The
LIP2pre sequence was made by hybridizing the synthetic
oligonucleotides LIP2prefw and LIP2prerv and cloning
the DNA between the BamHI and AvrII sites of
pYLHmA (pINA1291) [28] to produce pYLHUdL2pre.
The ManHDEL coding sequence was PCR amplified
from pGAPZMFManHDEL [18] using primers Man-
HDELfw and ManHDELrv and cloned Eco47III–AvrII in
pYLHUdL2pre, yielding pYLHUdL2preManHDEL. Next,
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one from pYLHmAX. pYLHmAX is pYLHmA with the
defective URA3d4 selection marker removed via NheI/
StuI and exchanged with the URA3 selection maker from
pKS-LPR-URA3 [26] via KpnI,T4 polymerase/AvrII. The
expression cassette (with LIP2preManHDEL under con-
trol of the constitutive promoter hp4d) from the result-
ant pYLHmAXL2preManHDEL was transformed to the
Y. lipolytica URA3-cured Δoch1 strain after digestion of
the plasmid with NotI and isolation of the fragment con-
taining the ManHDEL expression cassette.
In another construct, the T. reesei α-1,2 mannosidase
sequence was codon-optimized for expression in Y. lipo-
lytica (Geneart AG, Regensburg, Germany) and fused to
the LIP2pre signal sequence. This fusion construct was
expressed under control of four different promoters:
(i) hp4d, a Y. lipolytica hybrid promoter created by
Madzak et al. [19], (ii) GAP, the Y. lipolytica strong
constitutive glyceraldehyde-3-phosphate dehydrogenase
promoter, (iii) TEF1, the Y. lipolytica strong constitutive
translation elongation factor 1 promoter, and (iv) POX2,
the Y. lipolytica peroxisomal fatty-acyl-CoA oxidase2 pro-
moter. (i) The mannosidase was cloned in pYLHUXL2pre,
which is pYLHmAX with the LIP2pre sequence inser-
ted via BamHI-NcoI digestion, to produce the final
pYLHUXL2preManHDEL. (ii) pYLGmAX was construc-
ted by exchanging the hp4d promoter of pYLHmAX with
the GAPPfw-GAPPrv PCR amplified GAP promoter via
ClaI-BamHI digestion. The mannosidase was then
cloned in pYLGUXL2pre, which is pYLGmAX with
the LIP2pre sequence inserted via BamHI-NcoI diges-
tion, to produce the final pYLGUXL2preManHDEL. (iii)
pYLTmAX was constructed by exchanging the hp4d
promoter of pYLHmAX with the TEF promoter of
pYLTsA (pINA3313, a gift from J.M. Nicaud, INRA).
The mannosidase was then cloned in pYLTUXL2pre,
which is pYLTmAX with the LIP2pre sequence in-
serted via BamHI-NcoI digestion, to produce the final
pYLTUXL2preManHDEL. (iv) pYLPmAX was construc-
ted by exchanging the hp4d promoter of pYLHmAX
with the POX promoter of JMP62 (a gift from J.M.
Nicaud, INRA). The mannosidase was then cloned in
pYLPUXL2pre, which is pYLPmAX with the LIP2pre
sequence inserted via BamHI-NcoI digestion, to pro-
duce the final pYLPUXL2preManHDEL. All four plas-
mids were transformed to the Y. lipolytica URA3-cured
Δoch1 strain after digesting the plasmid with NotI
and isolating the fragment containing the ManHDEL
expression cassette.Selection marker rescue
For selection of the transformants, we made use of the
Cre-lox recombination system, in which the marker isflanked by loxP and loxR sites to facilitate efficient
marker rescue by transient overexpression of Cre re-
combinase. For overexpression of Cre recombinase, we
used pRRQ2 (a gift from of J.M. Nicaud, INRA) [26], in
which the enzyme open reading frame is under control
of the hp4d promoter, and which carries the LEU2
resistance gene. After transformation, strains were
grown for 48 h in selective drop-out medium (MM with
CSM –leu) and then tested for URA3 negative clones
in which recombination occurred using a replica tech-
nique with selective plates (CSM –ura and CSM –leu).
The URA3 gene was removed from two Δoch1
clones, and screening was done by Southern blot
analysis and PCR on gDNA using primers OCH1Pfw
and OCH1Trv.
Expression of glucocerebrosidase
The human glucocerebrosidase [GLCM, Swiss Prot entry
No. P04062, without the human signal sequence:
PRO_0000012177] was chemically synthesized as a
codon-optimized cDNA for expression in Y. lipolytica.
The coding sequence for the mature protein was fused
to the coding sequence of the LIP2pre signal sequence
and placed under control of the oleic acid inducible
POX2 promoter. This was done by cloning it Eco47III–
AvrII in pYLPUXL2pre digested with SacII, blunted with
T4 DNA polymerase and then digested with AvrII. The
resulting plasmid, pYLPUXL2preGLCM, was digested
with NotI before use.
Standard protein techniques
Protein expression of glucocerebrosidase controlled by the
POX promoter was based on induction with oleic acid.
YPD (5 mL) inoculated with precultures started from sin-
gle colonies grown on solid YPD medium was incubated
at 28°C for 16 h with rotation at 180 rpm. Sufficient pre-
culture was transferred to a 250 mL shake flask contain-
ing 25 mL of YTO medium to obtain a final OD600 of 0.2
and incubated at 28°C with rotation at 180 rpm. After
72 h of induction, 800 μL samples were taken. Culture
supernatants were precipitated using an acetone-deoxy-
cholate-trichloroacetic acid (DOC/TCA) mixture. Gluco-
cerebrosidase expression was analyzed by SDS-PAGE and
western blot. A rat monoclonal anti-glucocerebrosidase
antibody was used according to Alessandrini et al. [17].
Purification of glucocerebrosidase from the supernatant
of a Yarrowia Δoch1 strain was performed as follows: first
the medium was filtrated through a 0.22 μm filter and
then diafiltrated to a buffer at pH 6.0 containing 20 mM
sodium acetate, 20 mM bis-trispropane and 0.1% CHAPS.
This diafiltrate was passed over a Q-Sepharose column
and the flow through, containing glucocerebrosidase, was
collected. Upon adjusting the pH to 5, glucocerebrosidase
was purified over an S-Source omnifit column of 10 mL
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0.1% CHAPS, 1 M sodium chloride. Next, the enzyme
was polished by Superdex 75 (HR10 x30) gel filtration
chromatography with a buffer containing 20 mM triso-
dium citrate, 20 mM disodium hydrogen citrate, 0.01% (v/v)
0.15 M polysorbate 80 at pH 6). Remaining LPS after
the already performed purification steps is removed
by an extra injection of the final sample on a HiTrap
Q column of 1 mL using the same buffer. The final
concentration of glucocerebrosidase was approx. 1 mg/mL.
Specific activity of the purified glucocerebrosidase was
assessed with a hydrolysis assay for 4-Nitrophenyl β-D-
glucopyranoside (Sigma) in a microtitre plate format. One
enzyme unit is defined as the amount of enzyme that
catalyses the hydrolysis of 1 μmol of 4-Nitrophenyl-β-D-
glucopyranoside per minute at 37°C. Briefly, the purified
enzyme samples as well as the clinically used Cerezyme
positive control (Genzyme) were diluted in 50 mM sodium
citrate buffer, pH 5.0. 40 μL of such samples were
added to 160 μL of a 1 mM substrate solution in the
same buffer and incubated for 1 hour at 37°C. Then the
reaction was quenched by addition of 100 μL of 10% (w/v)
sodium carbonate buffer (pH 12), which also ionizes the
4-nitrophenol for absorbance measurement at 405 nm.
Upon blank substraction, the amount of product forma-
tion was calculated from a standard curve of a dilution
series of 4-nitrophenol (Sigma) treated in the same way.
Preparation of mannoproteins, N-glycan analysis and
exoglycosidase digests
Mannoproteins were prepared according to Ballou et al.
[29]. In brief, yeast strains were inoculated and grown
overnight in 10 mL YPD medium in 50 mL falcon tubes
at 28°C with rotation at 250 rpm. The cells were pelleted
at 4000 rpm in a cooled Eppendorf 5810R centrifuge.
They were first washed with 2 mL of 0.9% NaCl solution
and then twice with 2 mL of water, and then resus-
pended in 1.5 mL of 0.02 M sodium citrate pH 7. After
autoclaving for 90 min at 121°C, they were vortexed and
the cellular debris was removed by centrifugation. The
mannoproteins in the supernatant were precipitated
overnight with 4 volumes of methanol at 4°C on a rotat-
ing wheel. After centrifugation, the pellets were allowed
to dry and dissolved in 50 μL of water.
The whole 50 μL of the cell wall extract was used to
prepare N-glycans labeled with 8-aminopyrene-1.3.6-
trisulphonic acid (APTS) according to an established
method involving the blotting of the proteins to PVDF
[30]. Subsequently, fluorophore-assisted carbohydrate
electrophoresis (FACE) was performed with an ABI
3130 DNA sequencer.
APTS-labeled glycans were treated with α-1,2-manno-
sidase overnight at 37°C in 50 mM ammonium acetate
(pH 5.0).Competing interests
N C., K.D.P. and W.V. are inventors on a patent application claiming some of the
inventions in this publication. W.V. and A.V. are employees of Oxyrane Belgium N.
V. which has obtained the exploitation rights of this patent application.
Authors’ contributions
KDP: drafting the article; intellectual contribution. WV: acquisition and
analysis of data; intellectual contribution. ID: acquisition of data. AV:
acquisition of data. AVH: acquisition of data. NC: initiated and managed the
project, contributed to manuscript drafting. All authors read and approved
the final manuscript.
Acknowledgements
The authors thank Dr. Amin Bredan for the help in preparing the manuscript.
This work was supported by the Marie Curie Excellence Grant MEXT-014292
under EU Framework Program 6 and Oxyrane UK Ltd. (Manchester UK) and
the Fund for Scientific Research Flanders grant (FWO- G.0.541.08.N.10). We
thank Dr. Jean-Marc Nicaud and Dr. Jean-Marie Beckerich (CNRS-INRA)
Laboratoire Microbiologie et Génétique Moléculaire INRA, France, for
providing us with plasmids and strains. The extra support of Gwenda
Pynaert, Franck Fudalej and Stephen Depuydt is very much appreciated.
Author details
1Unit for Medical Biotechnology, Department for Molecular Biomedical
Research, VIB, Technologiepark 927, B-9052, Ghent, Belgium. 2Department of
Biochemistry and Microbiology, Ghent University, K.L.-Ledeganckstraat 35,
B-9000, Ghent, Belgium. 3Department of Biomedical Molecular Biology,
Ghent University, Technologiepark 927, B-9052, Ghent, Belgium. 4Oxyrane
Belgium, Technologiepark 3, B-9052, Ghent, Belgium.
Received: 26 April 2011 Accepted: 21 March 2012
Published: 1 May 2012
References
1. Kogelberg H, Tolner B, Sharma SK, Lowdell MW, Qureshi U, Robson M,
Hillyer T, Pedley RB, Vervecken W, Contreras R, Begent RHJ, Chester KA:
Clearance mechanism of a mannosylated antibody–enzyme fusion
protein used in experimental cancer therapy. Glycobiology 2006, 17:36–45.
2. Doebber TW, Wu MS, Bugianesi RL, Ponpipom MM, Furbish FS, Barranger JA,
Brady RO, Shen TY: Enhanced macrophage uptake of synthetically
glycosylated human placental beta-glucocerebrosidase. J Biol Chem 1982,
257:2193–2199.
3. Murray GJ: Lectin-specific targeting of lysosomal enzymes to
reticuloendothelial cells. Methods Enzymol 1987, 149:25–42.
4. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC,
Mankin HJ, Murray GJ, Parker RI, Argoff CE, Grewal RP, Yu K-T, Graham OC,
Holder CA, Howard KD, Kaneski CR, Oliver KL, Riesz S, Verderese CL, Zirzow GC:
Replacement therapy for inherited enzyme deficiency–macrophage-targeted
glucocerebrosidase for Gaucher's disease. N Engl J Med 1991, 324:1464–1470.
5. Sato Y, Beutler E: Binding, internalization, and degradation of
mannose-terminated glucocerebrosidase by macrophages.
J Clin Invest 1993, 91:1909–1917.
6. Madzak C, Gaillardin C, Beckerich JM: Heterologous protein expression
and secretion in the non-conventional yeast Yarrowia lipolytica: a
review. J Biotechnol 2004, 109:63–81.
7. Nakayama K, Nagasu T, Shimma Y, Kuromitsu J, Jigami Y: OCH1 encodes a
novel membrane bound mannosyltransferase: outer chain elongation of
asparagine-linked oligosaccharides. EMBO J 1992, 11:2511–2519.
8. Jungmann J, Munro S: Multi-protein complexes in the cis Golgi of
Saccharomyces cerevisiae with α-1,6-mannosyltransferase activity. EMBO J
1998, 17:423–434.
9. De Pourcq K, De Schutter K, Callewaert N: Engineering of glycosylation in
yeast and other fungi: current state and perspectives. Appl Microbiol
Biotechnol 2010, 87:1617–1631.
10. Barnay-Verdier S, Boisrame A, Beckerich JM: Identification and
characterization of two α-1,6-mannosyltransferases, Anl1p and Och1p, in
the yeast Yarrowia lipolytica. Microbiology 2004, 150:2185–2195.
11. Song Y, Choi MH, Park JN, Kim MW, Kim EJ, Kang HA, Kim JY: Engineering
of the yeast Yarrowia lipolytica for the production of glycoproteins
lacking the outer-chain mannose residues of N-glycans. Appl Environ
Microbiol 2007, 73:4446–4454.
De Pourcq et al. Microbial Cell Factories 2012, 11:53 Page 12 of 12
http://www.microbialcellfactories.com/content/11/1/5312. Stolz J, Munro S: The components of the Saccharomyces cerevisiae
mannosyl-transferase complex M-Pol I have distinct functions in mannan
synthesis. J Biol Chem 2002, 277:44801–44808.
13. Nakanishi-Shindo Y, Nakayama K, Tanaka A, Toda Y, Jigami Y: Structure of the
N-linked oligosaccharides that show the complete loss of α-1,6-polymannose
outer chain from och1, och1 mnn1, and och1 mnn1 alg3mutants of
Saccharomyces cerevisiae. J Biol Chem 1993, 268:26338–26345.
14. Yoko-o T, Tsukahara K, Watanabe T, Hata-Sugi N, Yoshimatsu K, Nagasu T,
Jigami Y: Schizosaccharomyces pombe och1+ encodes α-1,
6-mannosyltransferase that is involved in outer chain elongation of
N-linked oligosaccharides. FEBS Lett 2001, 489:75–80.
15. Vervecken W, Kaigorodov V, Callewaert N, Geysens S, De Vusser K, Contreras R:
In vivo synthesis of mammalian-like, hybrid-type N-glycans in Pichia
pastoris. Appl Environ Microbiol 2004, 70:2639–2646.
16. Kim MW, Kim EJ, Kim JY, Park JS, Oh DB, Shimma Y, Chiba Y, Jigami Y, Rhee SK,
Kang HA: Functional characterization of the Hansenula polymorpha HOC1,
OCH1, and OCR1 genes as members of the yeast OCH1
mannosyltransferase family involved in protein glycosylation. J Biol Chem
2006, 281:6261–6272.
17. Alessandrini F, Pfister S, Kremmer E, Gerber JK, Ring J, Behrendt H:
Alterations of glucosylceramide-beta-glucosidase levels in the skin of
patients with psoriasis vulgaris. J Invest Dermatol 2004, 123:1030–1036.
18. Callewaert N, Laroy W, Cadirgi H, Geysens S, Saelens X, Min Jou W,
Contreras R: Use of HDEL-tagged Trichoderma reesei mannosyl
oligosaccharide 1,2-α-D-mannosidase for N-glycan engineering in Pichia
pastoris. FEBS Lett 2001, 503:173–178.
19. Madzak C, Treton B, Blanchin-Roland S: Strong hybrid promoters and
integrative expression/secretion vectors for quasi-constitutive expression
of heterologous proteins in the yeast Yarrowia lipolytica. J Mol Microbiol
Biotechnol 2000, 2:207–216.
20. Romero PA, Sleno B, Herscovics A: Glycoprotein biosynthesis in
Saccharomyces cerevisiae. Partial purification of the α-1,6-
mannosyltransferase that initiates outer chain synthesis. Glycobiology
1994, 4:135–140.
21. Nakayama K, Nakanishi-Shindo Y, Tanaka A, Haga-Toda Y, Jigami Y:
Substrate specificity of α-1,6-mannosyltransferase that initiates N-linked
mannose outer chain elongation in Saccharomyces cerevisiae. FEBS Lett
1997, 412:547–550.
22. Gasmi N, Fudalej F, Kallel H, Nicaud JM: A molecular approach to optimize
hIFN α2b expression and secretion in Yarrowia lipolytica. Appl Microbiol
Biotechnol 2011, 89:109–119.
23. Fickers P, Fudalej F, Le Dall MT, Casaregola S, Gaillardin C, Thonart P, Nicaud JM:
Identification and characterisation of LIP7 and LIP8 genes encoding two
extracellular triacylglycerol lipases in the yeast Yarrowia lipolytica. Fungal
Genet Biol 2005, 42:264–274.
24. Barth G, Gaillardin C: Yarrowia lipolytica. In Nonconventional Yeasts in
Biotechnology. A Handbook. Edited by Wolf K. Berlin: Springer; 1996:313–388.
25. Barth G, Gaillardin C: Physiology and genetics of the dimorphic fungus
Yarrowia lipolytica. FEMS Microbiol Rev 1997, 19:219–237.
26. Fickers P, Le Dall MT, Gaillardin C, Thonart P, Nicaud JM: New disruption
cassettes for rapid gene disruption and marker rescue in the yeast
Yarrowia lipolytica. J Microbiol Methods 2003, 55:727–737.
27. Vervecken W, Callewaert N, Kaigorodov V, Geysens S, Contreras R:
Modification of the N-glycosylation pathway to produce homogeneous,
human-like glycans using GlycoSwitch plasmids. Methods Mol Biol 2007,
389:119–138.
28. Nicaud JM, Madzak C, van den Broek P, Gysler C, Duboc P, Niederberger P,
Gaillardin C: Protein expression and secretion in the yeast Yarrowia
lipolytica. FEMS Yeast Res 2002, 2:371–379.
29. Ballou L, Hernandez LM, Alvarado E, Ballou CE: Revision of the
oligosaccharide structures of yeast carboxypeptidase Y. Proc Natl Acad Sci
USA 1990, 87:3368–3372.
30. Laroy W, Contreras R, Callewaert N: Glycome mapping on DNA
sequencing equipment. Nat Protoc 2006, 1:397–405.
doi:10.1186/1475-2859-11-53
Cite this article as: De Pourcq et al.: Engineering the yeast Yarrowia
lipolytica for the production of therapeutic proteins homogeneously
glycosylated with Man8GlcNAc2 and Man5GlcNAc2. Microbial Cell Factories
2012 11:53.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
